Easy To Use Patents Search & Patent Lawyer Directory
At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.
This Patent May Be For Sale or Lease.
Register or Login To Download This Patent As A PDF
| United States Patent | 10,154,982 |
| Clarke , et al. | December 18, 2018 |
Ketone bodies and ketone body esters as blood lipid lowering agents
Abstract
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic .beta.-hydroxybutyrate or D-.beta.-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic .beta.-hydroxybutyrate or D-.beta.-hydroxybutyrate, esters of D-.beta.-hydroxybutyrate, oligomers of D-.beta.-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic .beta.-hydroxybutyrate or D-.beta.-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic .beta.-hydroxybutyrate or D-.beta.-hydroxybutyrate, esters of D-.beta.-hydroxybutyrate, oligomers of D-.beta.-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.
| Inventors: | Clarke; Kieran (Oxford, GB), Veech; Richard Lewis (Rockville, MD) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Applicant: |
| ||||||||||
| Assignee: |
OXFORD UNIVERSITY INNOVATION LIMITED
(Oxford,
GB)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC) |
||||||||||
| Family ID: | 1000003711086 | ||||||||||
| Appl. No.: | 14/931,265 | ||||||||||
| Filed: | November 3, 2015 |
| Document Identifier | Publication Date | |
|---|---|---|
| US 20160193173 A1 | Jul 7, 2016 | |
| Application Number | Filing Date | Patent Number | Issue Date | ||
|---|---|---|---|---|---|
| 12811648 | 9211275 | ||||
| PCT/US2009/030095 | Jan 5, 2009 | ||||
| 61018962 | Jan 4, 2008 | ||||
| Current U.S. Class: | 1/1 |
| Current CPC Class: | A61K 31/22 (20130101); A61K 9/0053 (20130101); A61P 3/10 (20180101); A61P 3/06 (20180101); A61K 45/06 (20130101); A61K 31/365 (20130101); A61K 31/19 (20130101); A61K 31/047 (20130101); A61K 31/047 (20130101); A61K 31/19 (20130101); A61K 31/22 (20130101); A61K 31/365 (20130101); A61K 2300/00 (20130101); A61K 2300/00 (20130101); A61K 2300/00 (20130101); A61K 2300/00 (20130101) |
| Current International Class: | A61K 31/22 (20060101); A61K 9/00 (20060101); A61K 31/19 (20060101); A61K 31/365 (20060101); A61K 45/06 (20060101); A61P 3/10 (20060101); A61P 3/06 (20060101); A61K 31/047 (20060101) |
| 3984566 | October 1976 | Van Scott et al. |
| 4380549 | April 1983 | Van Scott et al. |
| 5112865 | May 1992 | Nichels et al. |
| 5281691 | January 1994 | Hubbs et al. |
| 5654266 | August 1997 | Chen et al. |
| 5665831 | September 1997 | Neuenschwander et al. |
| 5693850 | December 1997 | Birkhahn et al. |
| 6126953 | October 2000 | Costa et al. |
| 6136862 | October 2000 | Hiraide et al. |
| 6207856 | March 2001 | Veech |
| 6316038 | November 2001 | Veech |
| 6323237 | November 2001 | Veech |
| 6380244 | April 2002 | Martin et al. |
| 6544960 | April 2003 | Eldred et al. |
| 6939570 | September 2005 | Snow et al. |
| 7351736 | April 2008 | Veech |
| 8101653 | January 2012 | Veech |
| 8642654 | February 2014 | Clarke |
| 2001/0047008 | November 2001 | Baraldi |
| 2002/0006959 | January 2002 | Henderson |
| 2002/0013339 | January 2002 | Martin et al. |
| 2002/0035231 | March 2002 | Whitehouse et al. |
| 2004/0063661 | April 2004 | Linnane |
| 2004/0171671 | September 2004 | Veech |
| 2004/0266872 | December 2004 | Veech et al. |
| 2005/0129783 | June 2005 | McCleary et al. |
| 2006/0078596 | April 2006 | Clarke et al. |
| 2006/0280721 | December 2006 | Veech et al. |
| 2008/0287372 | November 2008 | Henderson et al. |
| 2009/0197952 | August 2009 | Hashim et al. |
| 2009/0253781 | October 2009 | Veech |
| 2010/0298294 | November 2010 | Clarke et al. |
| 2011/0237666 | September 2011 | Clarke et al. |
| 2012/0064611 | March 2012 | Robertson et al. |
| 2012/0071548 | March 2012 | Veech |
| 2012/0213835 | August 2012 | Neas et al. |
| 2013/0102663 | April 2013 | Clarke et al. |
| 2014/0194509 | July 2014 | Clarke et al. |
| 2015/0250755 | September 2015 | Veech et al. |
| 1330307 | Jun 1994 | CA | |||
| 2173270 | Oct 1996 | CA | |||
| 1483355 | Sep 2002 | CN | |||
| 1552315 | Dec 2004 | CN | |||
| 20205184 | Dec 2002 | DE | |||
| 0 552 896 | Jul 1993 | EP | |||
| 1 568 780 | Aug 2005 | EP | |||
| 1 809 235 | Jul 2007 | EP | |||
| 1524611 | Sep 1978 | GB | |||
| 2511941 | Sep 2014 | GB | |||
| S54-138126 | Oct 1979 | JP | |||
| S63-112998 | May 1988 | JP | |||
| H01-095730 | Apr 1989 | JP | |||
| H01-160917 | Jun 1989 | JP | |||
| H03-083950 | Apr 1991 | JP | |||
| H04-112825 | Apr 1992 | JP | |||
| H07-076513 | Mar 1995 | JP | |||
| H10-175855 | Jun 1998 | JP | |||
| H10-265378 | Oct 1998 | JP | |||
| 2005247821 | Sep 2005 | JP | |||
| 2008127369 | Jun 2008 | JP | |||
| 2009532496 | Sep 2009 | JP | |||
| 2012500264 | Jan 2012 | JP | |||
| 507322 | Mar 1976 | SU | |||
| 1987003806 | Jul 1987 | WO | |||
| 1995009144 | Apr 1995 | WO | |||
| 1998041200 | Sep 1998 | WO | |||
| 2000004895 | Feb 2000 | WO | |||
| 2000015216 | Mar 2000 | WO | |||
| 2001013877 | Mar 2001 | WO | |||
| 2001051645 | Jul 2001 | WO | |||
| 2004105742 | Dec 2004 | WO | |||
| 2004108740 | Dec 2004 | WO | |||
| 2006020137 | Feb 2006 | WO | |||
| 2006070337 | Jul 2006 | WO | |||
| 2007001883 | Jan 2007 | WO | |||
| 2007063037 | Jun 2007 | WO | |||
| 2007115282 | Oct 2007 | WO | |||
| 2007115934 | Oct 2007 | WO | |||
| 2008119032 | Oct 2008 | WO | |||
| 2008140828 | Nov 2008 | WO | |||
| 2009023357 | Feb 2009 | WO | |||
| 2010021766 | Feb 2010 | WO | |||
| 2010120300 | Oct 2010 | WO | |||
| 2011101171 | Aug 2011 | WO | |||
| 2011121540 | Oct 2011 | WO | |||
| 2012113415 | Aug 2012 | WO | |||
| 2014071389 | May 2014 | WO | |||
Knowler et al., New Engl. J. Med. 346, 393-403 (2002). cited by examiner . Yaylali et al., Med. Sci. Res. 17, 1013-14 (1989). cited by examiner . Dashti et al., Mol. Cell Biochem. 286, 1-9 (2006). cited by examiner . Supplementary European Search Report and Written Opinion corresponding to European Patent Application No. 09701051.6, dated Jan. 19, 2011. cited by applicant . U.S. Appl. No. 13/580,602, filed Jan. 4, 2013 US 2013-0102663 A1 Apr. 25, 2013 Kieran Clarke. cited by applicant . U.S. Appl. No. 11/287,803, filed Nov. 28, 2005 US 2006-0078596 A1 Apr. 13, 2006 Kieran Clarke. cited by applicant . U.S. Appl. No. 10/559,258, filed Jun. 8, 2006 US 2006-0280721 A1 Dec. 14, 2006 Richard L Veech. cited by applicant . U.S. Appl. No. 12/811,648, filed Jul. 2, 2010 US 2010-0298294 A1 Nov. 25, 2010 Kieran Clarke. cited by applicant . U.S. Appl. No. 14/931,265, filed Nov. 3, 2015 Kieran Clarke. cited by applicant . U.S. Appl. No. 13/264,533, filed Oct. 14, 2011 US 2012-0064611 A1 Mar. 15, 2012 U.S. Pat. No. 9,034,613 May 19, 2015 Jeremy Robertson. cited by applicant . U.S. Appl. No. 14/213,713, filed Mar. 14, 2014 US 2014-0308719 A1 Oct. 16, 2014 Kieran Clarke. cited by applicant . U.S. Appl. No. 14/453,999, filed Aug. 7, 2014 US 2015-0065571 A1 Mar. 5, 2015 Kieran Clarke. cited by applicant . U.S. Appl. No. 14/390,495, filed Oct. 3, 2014 US 2015-0164855 A1 Jun. 18, 2015 Kieran Clarke. cited by applicant . U.S. Appl. No. 14/440,634, filed May 5, 2015 US 2015-0250755 A1 Sep. 10, 2015 Richard L. Veech. cited by applicant . U.S. Appl. No. 14/774,856, filed Sep. 11, 2015 Kieran Clarke. cited by applicant . U.S. Appl. No. 13/031,006, filed Feb. 18, 2011 US 2011-0237666 A1 Sep. 29, 2011 U.S. Pat. No. 8,642,654 Feb. 4, 2014 Kieran Clarke. cited by applicant . U.S. Appl. No. 14/101,834, filed Dec. 10, 2013 US 2014-0194509 A1 Jul. 10, 2014 Kieran Clarke. cited by applicant . "Drug Therapy of Dyslipidemia" in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., McGraw-Hill (New York), pp. 948-953 (2006). cited by applicant . Abdelwahab et al. (2012) "The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma," PLOS One. 7(5):E36197. pp. 1-7. cited by applicant . Boyarinov et al. (1984) "Effect of Sodium hydroxybutyrate on myocardial high-energy phosphates, function, and ultrastructure after blood loss", Biulleten' eksperimental'noT biologii i meditsiny. 97(3):289-292. cited by applicant . Buteau (2009) "Obviousness of Enantiomers over Prior Art Racemates," The Journal of High Technology Law. L22. pp. 42-49. cited by applicant . Clark et al. (2005) "Dilated Cardiomyopathy and Acute Liver Injury Associated with Combined Use of Ephedra, yHydroxybutyrate, and Anabolic Steroids" Pharmacotherapy. 25(5):756-761. cited by applicant . Davey et al. (1988) "Radioprotection of rat subependymal plate with 4-0H sodium butyrate," NCI Monogr. (6):231-234. cited by applicant . Desrochers et al. (1992) "Metabolism of R and S-1 ,3-butanediol in perfused livers from meal-fed and starved rats," Biochem. J. 285:647-653. cited by applicant . Desrochers et al. (1995) "Metabolism of {R,S)-1 ,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs," Am. J. Physiol. 268:E660-667. cited by applicant . Desrochers et al. (1995) "R, S-1, 3-butanediol acetoacetate esters, potential alternates to lipid emulsions for total parenteral nutrition," Journal of Nutritional Biochemistry. 6(2):111-118. cited by applicant . Eagles et al. (1997) "The effects of combined treatment with .beta.1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects," Brit. J. Clinical Pharmacol. 43:291-300. cited by applicant . Edegger et al. (2006) "Regia- and Stereoselective Reduction of Diketones and Oxidation of Dials by Biocatalytic Hydrogen Transfer," Eur. J. Org. Chem. 2006(8):1904-1909. cited by applicant . Felig et al. (1971) "Amino acid metabolism in exercising man." J. Clin. Invest. 50(12):2703-2714. cited by applicant . Goldbort et al. (1976) "Butanediols: Selection, open field activity, and NAD reduction by liver extracts in inbred mouse strains," Pharmacology Biochemistry and Behaviour. 5(3):263-268. cited by applicant . Kalaitzakis et al. (2005) "Highly Stereoselective Reductions of a-Aikyl-1 ,3-diketones and a-Aikyi-Jl-keto Esters Catalyzed by Isolated NADPH-Dependent Ketoreductases," Org. Lett. 7(22):4799-4801. cited by applicant . Kashiwaya et al. (2013) "A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease," Neurobiology of Aging. 34(6):1530-1539. cited by applicant . Kohut et al. (1995) "Effects of decresased free fatty acids on fatigue during exercise with carbohydrate feedings," Medicine and Science in Sports & Exercise. 27(5 Suppi):S102. cited by applicant . Kulinskii et al. (1993) "The radioprotective effect of GABA-tropic substances, gamma-hydroxybutyrate and piracetam," Radiobiologiia. 33(1):133-136.--English Abstract Only. cited by applicant . Larios et al. "Synthesis of flavor and fragrance esters using Candida antarctica lipase," Appl. Microbiol. Biotechnol. (2004) 65: 373-376. cited by applicant . Mori et al. (1987) "New synthesis of both enantiomers of grandisol, the boll weevil pheromon," Tetrahedron. 43(10):2229-2239. cited by applicant . Nair et al. (1988) "Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans," J. Clin. Invest. 82(1 ):198-205. cited by applicant . Neubauer et al. (1997) "Myocardial Phosphocreatine-to-ATP Ratio is a predictor of mortality in patients with dilated cardiomyopathy," Circulation. 96:2190-2196. cited by applicant . Ostrovskaya et al. (1981) "Effect of prolonged administration of sodium hydroxybutyrate on the working capacity and muscle tissue in rats," Farmakologiya I Toksikologiya. 44(5):534-539.--Only English Abstract Provided. cited by applicant . Puchowicz et al. (2000) "Dog model of therapeutic ketosis induced by oral administration of R,S-1 ,3-butanediol diacetoacetate," J. Nutr. Biochem. 11:281-287. cited by applicant . Rossi et al. (2000) "Suppression of Feed Intake after Parenteral Administration of D-1313--Hydroxybutyrate in Pygmy Goats," J. Vet. Med. A. 47:9-16. cited by applicant . Shaw et al. (1984) "Influence of beta-hydroxybutyrate infusion on glucose and free fatty acid metabolism in docs," Am. J. Phys. 247:E756-764. cited by applicant . Sherwin et al. (1975) "Effect of ketone infusions on amino acid and nitrogen metabolism in man" J. Clin. Invest. 55(6) 1382-1390. cited by applicant . Simons et al. ( 1982) "Long term treatment with Slow Release Oxprenolol Alone, or in Combination with other Drugs: Effects on Blood Pressure, Lipoproteins and Exercise Performance," Aust. N. Z. J. Med. 12:612-616. cited by applicant . Smith et al. (1975) "Initial effect of injury on ketone bodies and other blood metabolites," Lancet. 1(7897):1-3. cited by applicant . Tobin et al., "Effect of 1 ,3-Butanediol and Propionic Acid on Blood Ketones, lipids d Metal Ions in Rats", Journal of Nutrition, vol. 102, No. 8, 1972, pp. 1001-1008. cited by applicant . Turner et al. "Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)." Jama 281.21 (1999): 2005-2012. cited by applicant . Wu et al. (1987) "Ketone bodies inhibit leucine degradationin chick skeletal muscle," International J. of Biochem. 19(10 ):937-943. cited by applicant . Zhu et al. (2006) "A recombinant ketoreductase tool-box. Assessing the substrate selectivity and stereoselectivity toward the reduction of Jl-ketoesters," Tetrahedron. 62:901-905. cited by applicant . International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2009/040773, dated Oct. 18, 2011. cited by applicant . International Prelminary Report on Patentablility corresponding to International Patent Application No. PCT/US2009/030095, dated Jul. 6, 2010. cited by applicant . International Search Report corresponding to International Patent Application No. PCT/EP2013/069189, dated Aug. 12, 2014. cited by applicant . International Search Report corresponding to International Patent Application No. PCT/EP2014/055158, dated Jun. 25, 2014. cited by applicant . International Search Report corresponding to International Patent Application No. PCT/US2009/030095, dated Feb. 23, 2009. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2011/000833, dated Jun. 22, 2011. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/057250, dated Jun. 11, 2013. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/067027, dated Oct. 30, 2014. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/GB2004/002286, dated Oct. 11, 2004. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2004/018016, dated Apr. 15, 2005. cited by applicant . International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/068545, dated Jan. 20, 2014. cited by applicant . International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2009/040766, dated Aug. 6, 2009. cited by applicant . International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2009/040773, dated Feb. 22, 2010. cited by applicant . Search and Examination Report corresponding to Great Britain Patent Application No. 1404400.2, dated Mar. 26, 2014. cited by applicant . Search and Examination Report corresponding to Great Britain Patent Application No. 1404577.7, dated Oct. 23, 2014. cited by applicant . Search and Examination Report corresponding to Great Britain Patent Application No. 1414016.4, dated Aug. 29, 2014. cited by applicant . Search Report corresponding to Great Britain Patent Application No. 1002983.3, dated Jun. 10, 2010. cited by applicant. |
Primary Examiner: West; Theodore R.
Attorney, Agent or Firm:
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. Patent Application No. 12/811,648, filed Jul. 2, 2010, which is a U.S. National Stage Entry of International Patent Application No. PCT/US2009/030095, filed Jan. 5, 2009, which claims the benefit of U.S. Provisional Application Serial No. 61/018,962, filed Jan. 4, 2008, the disclosure of each of which is hereby incorporated by reference in its entirety, including all figures, tables and amino acid or nucleic acid sequences.
We claim:
1. A method for lowering serum cholesterol levels in a diabetic subject in need thereof comprising orally administering a composition comprising esters of D-.beta.-hydroxybutyrate, optionally in combination with an additional therapeutic agent, to the subject so as to raise blood D-.beta.-hydroxybutyrate plus acetoacetate from between 0.1 to 20 mM, between 0.5 and 10 mM or between 1 to 3 mM.
2. The method of claim 1, wherein said composition is administered in the form of the subject's diet.
3. The method of claim 1, wherein said method comprises administering a first composition comprising esters of D-.beta.-hydroxybutyrate in combination with a second composition comprising a therapeutic agent, wherein said first and second compositions are administered separately, sequentially or together and each composition is in a unit dosage form.
4. The method of claim 3, wherein said therapeutic agent is selected from glucose/blood sugar lowering agents, lipid lowering agents, blood pressure lowering agents, or agents that reduce inflammation.
5. The method of claim 1, wherein said method lowers or reduces blood sugar in the diabetic subject without inducing insulin shock and comprises feeding the diabetic subject a diet containing said composition.
6. The method of claim 1, wherein said method lowers or reduces elevated blood homocysteine and comprises administering said composition in a unit dosage form or feeding the diabetic subject a diet containing said composition.
7. The method of claim 1, wherein said method lowers or reduces serum C-reactive protein levels and comprises administering said composition in a unit dosage form or feeding the diabetic subject a diet containing said composition.
8. The method according to claim 1, wherein said method lowers or reduces blood pressure levels in a subject and comprises administering said composition in a unit dosage form or feeding the diabetic subject a diet containing said composition.
9. The method of claim 1, wherein the dietary intake of fat by the diabetic subject is reduced.
10. The method of claim 1, wherein esters of D-.beta.-hydroxybutyrate are administered in amounts that a) provide for blood levels of D-.beta.-hydroxybutyrate plus acetoacetate ranging from between 0.1 to 25 mM, between 0.4 to 10 mM or between 0.6 and 3 mM in the diabetic subject; or b) range from 2-100% of the total caloric intake of an individual, 5-70% of the total caloric intake of an individual, or 5-30% of the total caloric intake of the diabetic subject.
11. The method of claim 1, wherein esters of D-.beta.-hydroxybutyrate are administered in amounts that provide a reduction in serum cholesterol level, an increase in the ratio of HDL/LDL, or a reduction in serum cholesterol level and an increase in the ratio of HDL/LDL.
12. A method of reducing serum cholesterol levels in a diabetic subject in need thereof, comprising administering esters of D-.beta.-hydroxybutyrate in combination with a therapeutic agent selected from: a) anti-lipemic agents; b) anti-hypertensive agents; c) glucose lowering agents; or d) anti-inflammatory agents; to the diabetic subject.
13. The method of claim 12, wherein the diabetic subject is consuming a low fat diet.
14. The method of claim 12, wherein esters of D-.beta.-hydroxybutyrate are administered in amounts that a) provide for blood levels of D-.beta.-hydroxybutyrate plus acetoacetate ranging from 0.1 to 25mM, between 0.4 to 10 mM or between 0.6 and 3 mM in the diabetic subject; or b) range from 2-100% of the total caloric intake of an individual, 5-70% of the total caloric intake of an individual, or 5-30% of the total caloric intake of the diabetic subject.
BACKGROUND OF THE INVENTION
Vascular insufficiency, secondary to occlusive processes in the vasculature, constitutes a disease phenotype of wide applicability in a number of common disease states including among others: coronary insufficiency, cerebrovascular insufficiency, peripheral vascular insufficiency and impaired kidney perfusion. Among the major known predisposing factors causing narrowing of vasculature are: 1) elevated serum cholesterol, 2) elevated serum triglycerides, 3) elevated serum glucose, 4) elevated serum homocysteine, 5) certain inflammatory processes and 6) hypertension.
Ketone bodies cannot be utilized by liver, hence they can not be used to synthesize either triglycerides or cholesterol. Triglycerides and cholesterol are synthesized either from carbohydrates or lipids, which provide acetyl CoA, and thence respectively malonyl CoA or HMG CoA for the two synthetic pathways. The major source of blood cholesterol and triglyceride comes from liver where it is excreted into the blood as VLDL, the fatty acids of which are removed by various tissues to leave LDL in the blood.
The inventors of the subject patent application have found that feeding a subject a diet comprising, in part, esters or oligomers of the ketone body D-.beta.-hydroxybutyrate and lowered dietary fat can reverse a number of the known predisposing factors leading to vascular diseases.
BRIEF SUMMARY OF THE INVENTION
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or any combination thereof alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or any combination thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions (compositions combining racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or any combination thereof and a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or any combination thereof can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.
BRIEF DESCRIPTION OF THE TABLES
Table 1 provides details related to the diets fed to experimental animals.
Table 2 relates to plasma metabolite levels in non-fasting rats fed one of three diets for 7 or 66 days. The ketone diet doubled the plasma .beta.-hydroxybutyrate concentrations at both 7 and 66 days. Total cholesterol levels were significantly lower in ketone-fed rats compared with rats fed a Western diet. After 66 days on the diets, plasma HDL and LDL levels were significantly lower, and the HDL/LDL ratios tended to be higher, in the ketone fed rats compared with the Western-diet fed rats. The triacylglycerol levels were significantly lower in the rats fed the ketone diet, compared with rats fed the Western diet. There were no effects of diet on plasma free fatty acid levels, but the rats fed the ketone diet for 66 days had lower plasma glucose levels.
Table 3 provides a listing of combination therapies used for the treatment of hypertension.
DETAILED DESCRIPTION OF THE INVENTION
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof alone. Alternatively, compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions (compositions combining racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof and a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof can be administered alone in a normal diet, or in combination with other therapeutic agents to prevent or reverse vascular disease. In any of these embodiments, the compositions can be administered to a subject in combination with a low fat diet.
The subject application provides compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof in combination with: a) anti-lipemic agents; b) anti-hypertensive agents (including those combination treatments set forth in the table entitled "Combination Drugs for Treatment of Hypertension" [Table 3]); c) glucose lowering agents; or d) anti-inflammatory agents.
Non-limiting examples of anti-hypertensive agents that can be used in the formulation of compositions according to the subject invention include, and are not limited to, captopril (CAPOTEN), benazepril (LOTENSIN), enalapril (VASOTEC), lisinopril (PRINIVIL, ZESTRIL) fosinopril (MONOPRIL), ramipril (ALTACE), perindopril (ACEON), quinapril (ACCUPRIL), moexipril (UNIVASC), trandolapril (MAVIK), candesartan (ATACAND), eprosartan (TEVETAN), irbesartan (AVAPRO), telmisartan (MYCARDIS), valsartan (DIOVAN), losartan (COZAAR), atenolol (TENORMIN), propranolol (INDERAL), metoprolol (TOPROL), nadolol (CORGARD), betaxolol (KERLONE), acebutolol (SECTRAL), pindolol (VISKEN), bisoprolol (ZEBETA), hydrochlorothiazide (HYDRODIURIL), furosemide (LASIX), torsemide (DEMADEX), the combination of triamterene and hydrochlorothiazide (DYAZIDE), metolazone (ZAROXOLYN), ethacrynic acid, nisoldipine (SULAR), nifedipine (ADALAT, PROCARDIA), nicardipine (CARDENE), bepridil (VASCOR), isradipine (DYNACIRC), nimodipine (NIMOTOP), felodipine (PLENDIL), amlodipine (NORVASC), diltiazem (CARDIZEM), verapamil (CALAN, ISOPTIN), terazosin (HYTRIN), doxazosin (CARDURA), tamsulosin (FLOMAX), alfuzosin (UROXATRAL) or clonidine (CATAPRES) and the combination therapies disclosed in the table below (entitled "Combination Drugs for Treatment of Hypertension" (Table 3)). These agents are formulated with racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof to provide compositions useful for the reduction or lowering hypertension in treated subjects. These compositions can also be used to prevent or reverse vascular disease in a subject.
With respect to glucose lowering agents, there are four major classes of oral glucose lowering agents. These include the biguanides (e.g., metformin), sulfonylureas (e.g., glyburide), thiazolidinediones and alpha-glucosidase inhibitors. Thus, the subject invention also provides compositions comprising D D-.beta.-hydroxybutyrate and esters or precursors thereof in combination with biguanides (e.g., metformin), sulfonylureas (e.g., glyburide), thiazolidinediones and/or alpha-glucosidase inhibitors that are useful for lowering blood glucose levels in a subject.
The subject invention also provides compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof in combination with anti-lipemic agents (e.g., probucol, niacin, omega 3 ethyl esters or omega 3 fatty acids), bile acid sequesterants (e.g., cholestyramine, cholestyramine-sucrose, cholestyramine-aspartame, colesevelam or colestipol), cholesterol absorption inhibitors (e.g., ezetimibe or ezetimibe-simvastatin) fibric acid derivatives (e.g., fenofibrates or gemfibrozil), and/or HMG-CoA reductase inhibitors (amlodipine-atorvastatin, atorvastatin, fluvastatin, lovastatin, niacin-lovastatin, pravastatin, rosuvastatin, simvastatin). Such compositions can be used to reduce or lower serum cholesterol levels or triglyceride levels in a subject.
Compositions comprising anti-inflammatory agents and racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof are also provided by the subject application. Anti-inflammatory agents include, but are not limited to: aspirin, salsalate, diflunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, ketorolac, oxaprozin or celecoxib. Thus, the subject invention also provides for the treatment of inflammation comprising the administration of compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof alone, or in combination with anti-inflammatory agents.
The subject invention also provides for the use of the aforementioned compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof for the preparation of a medicament for lowering or reducing serum cholesterol; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in a subject. The use described in this paragraph can optionally comprise the administration of the aforementioned compositions to a subject in conjunction with the administration of a low fat diet to a subject.
Thus, in one embodiment of the invention, a use of a composition, as described above, comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic 3-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof (alone or in combination with other agents (e.g., a) anti-lipemic agents; b) anti-hypertensive agents (including those combination treatments set forth in Table 3, entitled "Combination Drugs for Treatment of Hypertension"); c) glucose lowering agents; or d) anti-inflammatory agents)) to lower or reduce serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in a subject is provided. These compositions can be administered to a subject orally (e.g., in the form of the diet of the subject (a nutritional composition for example) or via the administration of therapeutic compositions comprising racemic 3-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof), parenterally, via injection or rectally. Again, the compositions described herein can be administered alone or in conjunction with a low fat diet to the subject.
In certain preferred embodiments, the methods of the subject application comprise the oral administration of compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof. These orally administered compositions have the benefit of lowering serum cholesterol, triglyceride and/or glucose levels in a subject, including those instances where the compositions are orally administered as a part of a low fat diet to the subject. For the purposes of this invention, the term "subject" is directed to mammals and, in certain embodiments, humans. "Administering" "administered" or "administer" is defined as the introduction of the disclosed compositions into a subject via oral, nasal, ocular, rectal, vaginal and parenteral routes.
Compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof may be administered alone (e.g., a composition comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof and lacking any other therapeutic ingredient) or in combination with other agents (e.g., a) anti-lipemic agents; b) anti-hypertensive agents (including those combination treatments set forth in Table 3, entitled "Combination Drugs for Treatment of Hypertension"); c) glucose lowering agents; or d) anti-inflammatory agents) via any route of administration and, optionally, in conjunction with the administration or intake of a low fat diet by the subject. These routes of administration include, and are not limited to, subcutaneous (SQ), intramuscular (IM), intravenous (IV), intraperitoneal (IP), intradermal (ID), via the nasal, ocular or oral mucosa (IN), or orally (PO). When the compositions disclosed herein are administered orally, the compositions can be provided to the subject in the form of the diet eaten by the subject or in pills or other unit dose forms. A unit dose form can be a packaged preparation, such as packeted tablets, capsules, and powders in paper or plastic containers or in vials or ampoules. Also, the unit dosage can be a liquid based preparation or formulated to be incorporated into solid food products, chewing gum, or lozenge. As described herein, the phrase "in combination" is to be interpreted as the administration of compositions comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof with other agents either together (in a single composition), separately (i.e., a first composition comprising racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof and a second composition comprising another agent (e.g., a) anti-lipemic agents; b) anti-hypertensive agents (including those combination treatments set forth in the table entitled "Combination Drugs for Treatment of Hypertension" [Table 3]); c) glucose lowering agents; or d) anti-inflammatory agents)) or sequentially. For the sequential administration of a first and second composition to be considered a combination therapy (e.g., "in combination"), the first and second compositions must be administered separated by a time interval that still permits the first composition to be used during a treatment cycle of the second composition, or that permits the first composition to show enhanced activity, particularly activity, when compared with the single components alone. In the context of this invention, the term "activity" relates to an ability to lower serum cholesterol levels; triglyceride levels; serum glucose levels, blood sugar levels, serum homocysteine levels, inflammatory proteins, inflammation or blood pressure/hypertension.
Racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof are administered to an individual in an amount that results in blood concentrations of between 0.1 to 25 mM of D D-.beta.-hydroxybutyrate plus acetoacetate, or preferably between 0.4 to 10 mM or most preferred between 0.6 and 3 mM blood levels of D D-.beta.-hydroxybutyrate plus acetoacetate. Alternatively, the methods may recite the levels of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof that are to be administered to an individual in terms of percentages. Thus, racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol, or any combination thereof can be administered in amounts that range from 2-100% of the diet of an individual, or preferably 5-70% of the diet of an individual, or most preferred 5-30% of the diet of the individual. These percentages refer to the total caloric intake of the individual. Additionally, any combination of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (optionally in the acid form), physiologically compatible salts of racemic .beta.-hydroxybutyrate or D D-.beta.-hydroxybutyrate (e.g., sodium, potassium, calcium or magnesium salts), esters of D D-.beta.-hydroxybutyrate, oligomers of D D-.beta.-hydroxybutyrate containing from 2 to 20 (or more) monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol can be administered to an individual in accordance with the aforementioned methods.
EXAMPLES
Animals were fed diets comprising the various components as set forth in Table 1. The animals were then tested to determine total cholesterol levels, low density lipoprotein levels, high density lipoprotein levels, triacylglycerol levels, free fatty acid levels and plasma glucose levels. Table 2 relates to plasma metabolite levels in non-fasting rats fed one of three diets for 7 or 66 days. The ketone diet doubled the plasma .beta.-hydroxybutyrate concentrations at both 7 and 66 days. Total cholesterol levels were significantly lower in ketone-fed rats compared with rats fed a Western diet. After 66 days on the diets, plasma HDL and LDL levels were significantly lower, and the HDL/LDL ratios tended to be higher, in the ketone fed rats compared with the Western-diet fed rats. The triacylglycerol levels were significantly lower in the rats fed the ketone diet, compared with rats fed the Western diet. There were no effects of diet on plasma free fatty acid levels, but the rats fed the ketone diet for 66 days had lower plasma glucose levels.
TABLE-US-00001 TABLE 1 Diet macronutrient composition. All diets contained the same energy (kcal/g), but had different macronutrients. Energy Fat Protein Carbohydrate Ketone Diet (kcal/g) (% kcal) Western 1.76 34 27 39 0 Carbohydrate 1.76 4 26 70 0 Ketone 1.76 4 27 39 30
TABLE-US-00002 TABLE 2 Non-fasting rat plasma metabolite levels measured after feeding a Western, high carbohydrate or ketone diet for 7 (upper section) or 66 .+-. 3 days (lower section). Plasma metabolites Western diet Ketone diet after 7 days on diet (n = 10) (n = 10) .beta.-Hydroxybutyrate (mM) 0.41 .+-. 0.03 0.85 .+-. 0.10*** Cholesterol (mM) 1.9 .+-. 0.1 1.2 .+-. 0.1*** Triacylglycerol (mM) 1.95 .+-. 0.15 0.79 .+-. 0.11** Free fatty acids (mM) 0.11 .+-. 0.01 0.15 .+-. 0.02 Glucose (mM) 15 .+-. 1 14 .+-. 1 Plasma metabolites Western diet Carbohydrate diet Ketone diet after 66 days on diet (n = 10) (n = 10) (n = 10) .beta.-Hydroxybutyrate 0.48 .+-. 0.06 0.59 .+-. 0.14 0.91 .+-. 0.20* (mM) Cholesterol (mM) 2.3 .+-. 0.2 1.6 .+-. 0.2 1.1 .+-. 0.1*** HDL (mM) 0.69 .+-. 0.03 0.47 .+-. 0.04*** 0.33 .+-. 0.05*** LDL (mM) 0.22 .+-. 0.03 0.13 .+-. 0.03* 0.09 .+-. 0.02*** HDL/LDL 3.4 .+-. 0.3 4.2 .+-. 0.6 4.4 .+-. 0.5 Triacylglycerol (mM) 1.11 .+-. 0.13 0.92 .+-. 0.09 0.67 .+-. 0.11*** Free fatty acids (mM) 0.23 .+-. 0.09 0.23 .+-. 0.03 0.26 .+-. 0.04 Glucose (mM) 12.8 .+-. 0.42 14.9 .+-. 2.1 8.6 .+-. 1.1** *P < 0.05; **P < 0.01; ***P < 0.001 vs. Western diet.
TABLE-US-00003 TABLE 3 Combination Drugs for Treatment of Hypertension amiloride and hydrochlorothiazide spironolactone and hydrochlorothiazide triamterene and hydrochlorothiazide triamterene and hydrochlorothiazide atenolol and chlorthalidone bisoprolol and hydrochlorothiazide metoprolol and hydrochlorothiazide nadolol and bendroflumethazide propranolol and hydrochlorothiazide propranolol and hydrochlorothiazide timolol and hydrochlorothiazide benazepril and hydrochlorothiazide captopril and hydrochlorothiazide enalapril and hydrochlorothiazide lisinopril and hydrochlorothiazide lisinopril and hydrochlorothiazide moexipril and hydrochlorothiazide losartan and hydrochlorothiazide valsartan and hydrochlorothiazide amlodipine and benazepril diltiazem and enalapril felodipine and enalapril verapamil and trandolapril clonidine and chlorthalidone hydralazine and hydrochlorothiazide methyldopa and hydrochlorothiazide prazosin and polythiazide
File A Patent Application
- Protect your idea -- Don't let someone else file first. Learn more.
- 3 Easy Steps -- Complete Form, application Review, and File. See our process.
- Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.